« Return to News | Drug Sponsors

Xention, Ono continue collaboration

Tuesday, April 12, 2011 11:21 AM

Xention, a Cambridge, U.K.-based biopharmaceutical company that discovers and develops ion channel-modulating drugs, will extend its collaboration with Ono Pharmaceutical.  The two-year agreement between the companies began in March 2009.  The collaboration has been successful in identifying multiple compounds that selectively modulate the function of target ion channels, and the two have agreed to extend the drug-discovery collaboration for another year.

Xention is applying its proprietary ion channel drug discovery platform to the identification, design and synthesis of small molecules against ion channels selected by Ono.  Ono is responsible for subsequent pre-clinical, clinical development and worldwide commercialization of potential new pharmaceutical products arising from the collaboration.

Ono will continue to fund the research program in its entirety, and Xention will receive milestone fees on meeting specified drug-discovery targets and on Ono’s achievement of development and regulatory goals.  Xention will also receive royalties on the sales of successfully commercialized products.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.